Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report

Afatinib, a selective and irreversible ErbB family blocker, has recently been shown to provide a more favorable clinical outcome compared with gefitinib and erlotinib in patients with EGFR-mutant NSCLC and squamous NSCLC, respectively.1Park K. Tan E.H. O'Byrne K. et al.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled...